We are dropping analyst coverage of Intrepid Potash . We provide broad coverage of more than 1,500 companies across more than 90 industry groups and adjust our coverage as necessary based on client demand and investor interest.
Millennium Pharmaceuticals for sales of IPI -145, Infinity's oral PI3K inhibitor ..... to Millennium future royalties related to IPI -145 in oncology. Infinity may exercise ..... that gain regulatory approval, including IPI -145. The remaining payments include up
cancers, several competitors are following close behind. Gilead's idelalisib has recently been approved and Infinity's IPI -145, and AbbVie/Roche's ABT-199 are in Phase III studies. Earlier-stage Ono Pharmaceutical's ONO-4059 and Celgene
but we'll be keeping an eye out to make sure management doesn't make a habit out of raising project cost estimates. Intrepid Potash is a U.S. producer of potash (1,000,000 tons of capacity) and langbeinite (240,000 tons of capacity) operating
We’re raising our fair value estimate for Intrepid Potash to $16 per share from $15 per share following the release of second-quarter results. Our fair value estimate boost reflects
Intrepid Potash (NYSE: IPI ): Q2 EPS of $0.07 beats by $0.06 . Revenue of $110.95M (+19.7% Y/Y) beats by $19.91M . Press Release Post your comment!
ESRT , ESV , EXL , EXR , FBHS , FEIC , FISH , FMC , FNF , FOE , FORM , FORR , GLUU , HIG , HK , HOLX , HOS , HR , HTH , INT , IPI , ISIL , KBR , KEX , KGC , KRFT , KS , LGCY , LNC , LOCK , LPSN , LRCX , MAA , MANT , MDAS , MEOH , MET , MOBL , MOH , MTGE
We're holding steady on our $15-per-share fair value estimate for Intrepid Potash following the release of the company's first-quarter results. Our no-moat rating remains intact. Despite a big jump in
heavily on fertilizer mix at the individual company level. For example, the effect will be much greater on pure-play Intrepid Potash than diversified Agrium. We also expect to re-examine other parts of our valuations for potash producers when implementing
We're holding steady on our $13 per share fair value estimate for Intrepid Potash following the release of the firm's full-year results and forecast for 2014. Our no moat rating remains intact. The firm